H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Merus to $65 from $48 and keeps a Buy rating on the shares. The analyst says petosemtamab “is poised to show its full potential” in Q2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRUS:
- Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
- Merus NV (MRUS) Q4 Earnings Cheat Sheet
- Merus price target raised to $56 from $48 at Guggenheim
- Merus price target raised to $44 from $38 at BofA
- Merus to Participate in Upcoming Investor Conferences